Given the evidence linking ATAD2 to paclitaxel resistance across multiple cancers, particular attention should be given to assessing these compounds in paclitaxel-resistant models, with in vivo validation using resistant xenografts to support clinical translation. Here, ATAD2 is linked to cancer.